12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Company News  |  Deals

Summit deal

Summit received a $250,000 milestone payment from not-for-profits, including the Muscular Dystrophy Association, under a December 2011 deal providing $1.5 million in funding for a dose-escalation Phase I trial of SMT C1100 to treat Duchenne muscular...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >